OncoDNA announces the closing of a round C financing of 6,5 M€

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the closing of a Round C financing of 6,5 M€, entirely subscribed by its current shareholders.

Both private (including Vesalius BioCapital III, Ackermans & van Haaren, , Swisscanto, CPH bank) and public (SFPI, Wallonie Entreprendre and Sambrinvest), along with management and long-time individual investors, have participated in this round of financing with the objective of supporting the Company in achieving its strategic plan. This plan consists of achieving double digit, profitable, sustainable growth in personalized medicine, and reaching profitability.

As a European leader in this field, OncoDNA will be able to continue developing molecular profiling offers for clinicians, researchers and bio-pharmaceutical companies based on its differentiated offerings such as the OncoDEEP Kit, a pan-cancer genomic panel that utilizes the ability to locally perform the sequencing while benefiting from more than 100k profiles available in its central database developed since 2012. The results are readily available through the cloud-based, user friendly KDM interface.

In parallel, OncoDNA’s governance has been simplified with a more compact Board of Directors, now chaired by Charles-André Brouwers (CAB), Managing Partner at Galileo Life Sciences, and comprised of 5 Directors.

Jean Stephenne, co-founder and former Chairman of the board declared “It is with great confidence that I hand over the reins of OncoDNA’s board to Charles-André, to lead the Company towards profitability and success. The last ten years of OncoDNA have been a terrific adventure, creating a European champion in personalized medicine, with the acquisition of Biosequence in Spain in 2016 and IntegraGen in France in 2020, we look forward to continuing the journey.”

C-A Brouwers added “It is a great pride to chair this group of committed shareholders that has reiterated its commitment to fully support the management, in order to achieve the company’s strategy of profitable growth and delivering the promises of personalized medicine.”

ABOUT ONCODNA

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data interpretation software, and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – Biosequence and IntegraGen – are based in Spain, France and the United States. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.

For further information, connect with us on LinkedIn or Facebook.

CONTACTS

BERNARD COURTIEU
CEO

You may also be interested in these resources

Scientific Application Note

MELANOMA: The addition of PD-L1 blockade (atezolizumab) to combined BRAF/MEK inhibition (vemurafenib + cobimetinib) improved PFS as first line therapy in advanced BRAF V600 mutant melanoma. Survival data are awaited

CT012 – Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial ABSTRACTBACKGROUND: Approved systemic treatments for advanced melanoma include immune...

Share This